Cancer

Greco2

GRECO-2: A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer

Trial overview

Disease

Pancreatic cancer

Topic

Greco2

Sponsor

Description

GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic

Study details

For detailed information on this trial, please click here.

Trial status

Open in the UK

Location

Principle Investigator

Dr James Good

MSc PhD FRCR

Clinical Oncologist

Birmingham +1